Loading stock data…
CATX
$3.85-0.05 (-1.28%)
Market ClosedLast close May 1
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Perspective Therapeutics, Inc. in the Healthcare sector is trading at $3.85. The stock is currently 38% below its 52-week high of $6.16, remaining 5.8% above its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why CATX maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.85
Potential Upside
5%
Whystock Fair Value$4.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus15 analysts
Mean target$13.00+237.7%
Range$7.00 – $18.00
Fundamentals
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$548.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.87
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.81%
Volume
Today's trading volume
1.00M
Recent News
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress
Perspective Therapeutics Inc. (NYSE:CATX) is one of the best high-return penny stocks to buy right now. On February 2, Perspective Therapeutics Inc. (NYSE:CATX) priced an underwritten offering of 39.57 million shares at $3.78 per share. The company anticipates gross proceeds of $175 million from the offering. It plans to use the net proceeds from the […]
Perspective Therapeutics (CATX) Is Up 92.6% After $175M Equity Raise To Fund Targeted Alpha Therapies – Has The Bull Case Changed?
Perspective Therapeutics recently completed a US$174.99 million follow-on equity offering, issuing 39,576,088 shares of common stock at US$3.79 and 6,598,046 pre-funded warrants at US$3.789, as it works to advance its cancer-focused targeted alpha therapies program. This capital raise follows encouraging interim Phase 1/2a data for lead candidate VMT-α-NET using the alpha-emitting isotope Lead-212, which has drawn increased attention from the oncology and investment communities. We will now...
A Look At Perspective Therapeutics (CATX) Valuation After New VMT-α-NET Trial And Pipeline Updates
Perspective Therapeutics (CATX) drew fresh attention after updated interim data from its Phase 1/2a VMT-a-NET trial showed sustained anti-tumor activity, along with a business update on pipeline priorities and manufacturing expansion plans. See our latest analysis for Perspective Therapeutics. The recent VMT-a-NET update arrived after a sharp rise in the share price, with a 39.85% 7-day share price return and a 45.77% 90-day share price return. Meanwhile, the 1-year total shareholder return...
Perspective Therapeutics: Q3 Earnings Snapshot
SEATTLE (AP) — Perspective Therapeutics, Inc. CATX) on Monday reported a loss of $26 million in its third quarter. The Seattle-based company said it had a loss of 35 cents per share.
Stevanato Group (STVN) Q3 Earnings and Revenues Surpass Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +14.29% and +5.54%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?